Nrc Health (NRC) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Nrc Health (NRC) stock forecast summary
On Oct. 16, 2026, NRC is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5171 stocks scored that day.
Nrc Health is a small-cap company with a market capitalization of $446M. It ranks number 8 by market capitalization among the 15 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast. Its D/E Ratio of 19.79x is the highest of the 11 peers that report one.
For NRC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 49.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 41.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NRC included.
Follow NRC freeNRC price chart and AI forecast
How NRC ranks among 5171 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Nrc Health (NRC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Financial statement data is not available for this company: its filings are not in a form the pipeline converts, so only market data is shown.
Valuation & Market
| Metric | NRC | Rank |
|---|---|---|
| Market Cap | $446M | 8/15 |
Profitability & Margins
| Metric | NRC | Rank |
|---|---|---|
| ROIC | 14.6% | 5/11 |
| Operating Margin | 10.5% | 4/13 |
| EBT Margin | 6.7% | 5/13 |
| Tax Rate | 37.6% | – |
Financial Health
| Metric | NRC | Rank |
|---|---|---|
| Current Ratio | 0.65x | 11/16 |
| D/E Ratio | 19.79x | 1/11 |
| Financial Leverage | 20.79x | 1/10 |
Cash Flow
| Metric | NRC | Rank |
|---|---|---|
| FCF/Sales | 15.5% | 2/8 |
| CapEx/Sales | 5.6% | 2/8 |
Operational Efficiency
| Metric | NRC | Rank |
|---|---|---|
| Asset Turnover | 1.03x | 2/8 |
| Receivables Turnover | 15.0x | 1/7 |
| Fixed Assets Turnover | 3.5x | 6/9 |
| Days Sales Outstanding | 24 days | 7/7 |
Dividend & Shareholder Information
| Metric | NRC | Rank |
|---|---|---|
| Shares Outstanding | 22M | – |
NRC quarterly financials and insider trading
Nrc Health (NRC) industry peers
Companies classified under the same SEC industry code as Nrc Health (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| NRC Nrc Health | ▶ | $446M |
| IQV Iqvia Holdings Inc. | ▼ | $45.37B |
| INCY Incyte Corp | ▼ | $22.20B |
| MEDP Medpace Holdings, Inc. | ▼ | $17.26B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.33B |
| ICLR Icon Plc | ▶ | $13.13B |
| ABSI Absci Corp | ▲ | $1.42B |
| OABI Omniab, Inc. | ▲ | $667M |
| MXCT Maxcyte, Inc. | ▲ | $134M |
| ONMD Onemednet Corp | ▲ | $28M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | $5M |
| BUDZ Weed, Inc. | ▲ | $3M |
| ISPC Ispecimen Inc. | ▼ | $3M |
| FOXO Foxo Technologies Inc. | ▼ | $180K |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
Where NRC sits on the market map
Nrc Health (NRC) stock news
Loading...
Nrc Health (NRC) stock forecast FAQ
What is the Nrc Health (NRC) stock forecast?
On Oct. 16, 2026, NRC is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5171 stocks scored that day.
How accurate are Nrc Health stock predictions?
For NRC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 49.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 41.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Nrc Health forecasts updated?
Nrc Health forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Nrc Health's industry peers?
16 issuers in our coverage, NRC included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.